Controlled Trial Methodology and Progress in Treatment of the Acquired Immunodeficiency Syndrome (AIDS)
Authors: Samuel Broder
Journal: Annals of Internal Medicine (1989)

Editorials15 March 1989Controlled Trial Methodology and Progress in Treatment of the Acquired Immunodeficiency Syndrome (AIDS)A Quid ProQuoSamuel Broder, MDSamuel Broder, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-6-417 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe acquired immunodeficiency syndrome (AIDS) and its related disorders are caused by a retrovirus now called human immunodeficiency virus, type 1 (HIV-I) (1). Four years ago, pathogenic retrovirus infections were viewed by many scientists and clinicians as inherently untreatable. This idea militated against offering patients, or society at large, even the most cautious sense of optimism, and scientists assumed the uncomfortable role of preparing the public for the worst. The prevailing view was that there might not beanythingworth testing in large-scale clinical trials and that for the foreseeable future no therapy would make a substantial impact against the...References1. GalloMontagnier RL. The chronology of AIDS research. Nature. 1987;326:435-6. CrossrefMedlineGoogle Scholar2. YarchoanKleckerMarkham RRP. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986;1:575-80. CrossrefMedlineGoogle Scholar3. MitsuyaBroder HS. Strategies for antiviral therapy in AIDS. Nature. 1987;325:773-8. CrossrefMedlineGoogle Scholar4. Broder S. Identification of therapies against retroviruses, pp 569-74. In: DeVita VT Jr, moderator. Developmental therapeutics and the acquired immunodeficiency syndrome. Ann Intern Med. 1987; 106:568-81. LinkGoogle Scholar5. HirschKaplan MJ. Treatment of human immunodeficiency virus infections. Antimicrob Agent Chemother. 1987;31:839-43. CrossrefMedlineGoogle Scholar6. De Clercq E. Perspectives for the chemotherapy of AIDS. Anticancer Res. 1987;7:1023-38. MedlineGoogle Scholar7. YarchoanMitsuyaBroder RHS. Therapeutic strategies in the treatment of AIDS. Ann Rep Med Chem. 1988;23:253-65. Google Scholar8. FischlRichmanGrieco MDM. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-91. CrossrefMedlineGoogle Scholar9. YarchoanBergBrouwers RGP. Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet. 1987;1:132-5. CrossrefMedlineGoogle Scholar10. PizzoEddyFalloon PJJ. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988;319:889-96. CrossrefMedlineGoogle Scholar11. SchmittBigleyMcKinnis FJR. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988;319:1573-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Samuel Broder, MDAffiliations: National Cancer Institute Bethesda, Maryland Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEthical Dilemmas in HIV Infection: What Have We Learned?Toward the Rational Design of Antiretroviral Therapy for Human Immunodeficiency Virus (HIV) InfectionThe rise of the British pharmaceutical industry.Development of a rational practice of therapeutics.Community-Based AIDS ResearchIn Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-DideoxyinosineAIDS — Medizinische, epidemiologische und psychosoziale Faktoren 15 March 1989Volume 110, Issue 6Page: 417-418KeywordsAIDSClinical trialsForecastingHIV-1Medical servicesPathogensRetrovirusesScientists ePublished: 1 December 2008 Issue Published: 15 March 1989 PDF downloadLoading ...